138 related articles for article (PubMed ID: 37909009)
1. Protein disulfide isomerase A3 as novel biomarker for endometrial cancer.
Yu F; Liu X; Li M; Liu X; Wang X; Guo M
Front Oncol; 2023; 13():1247446. PubMed ID: 37909009
[TBL] [Abstract][Full Text] [Related]
2. Protein Disulfide-Isomerase A3 Is a Robust Prognostic Biomarker for Cancers and Predicts the Immunotherapy Response Effectively.
Tu Z; Ouyang Q; Long X; Wu L; Li J; Zhu X; Huang K
Front Immunol; 2022; 13():837512. PubMed ID: 35401558
[TBL] [Abstract][Full Text] [Related]
3. Expression and Prognostic Significance of PDIA3 in Cervical Cancer.
Zhang J; Li H; Li H; Lin D; Wang X; Wang K
Int J Genomics; 2022; 2022():4382645. PubMed ID: 36406049
[TBL] [Abstract][Full Text] [Related]
4. The role of PDIA3 in oral squamous cell carcinoma and its value as A diagnostic and prognostic biomarker.
Wang L; Wang X; Zhang J; Duan J; Tang C; Zhang L; Zeng H; Li H; Li Y; Zhou Y
Heliyon; 2023 Dec; 9(12):e22596. PubMed ID: 38213579
[TBL] [Abstract][Full Text] [Related]
5. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
Zhang J; Wang K; Hainisayimu T; Li H
Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
[TBL] [Abstract][Full Text] [Related]
6. Protein disulfide isomerase A3-specific Th1 effector cells infiltrate colon cancer tissue of patients with circulating anti-protein disulfide isomerase A3 autoantibodies.
Caorsi C; Niccolai E; Capello M; Vallone R; Chattaragada MS; Alushi B; Castiglione A; Ciccone G; Mautino A; Cassoni P; De Monte L; Álvarez-Fernández SM; Amedei A; Alessio M; Novelli F
Transl Res; 2016 May; 171():17-28.e1-2. PubMed ID: 26772958
[TBL] [Abstract][Full Text] [Related]
7. Correlation between low expression of protein disulfide isomerase A3 and lymph node metastasis in papillary thyroid carcinoma and poor prognosis: a clinicopathological study of 1,139 cases with long-term follow-up.
Kure S; Chiba T; Ebina A; Toda K; Jikuzono T; Motoda N; Mitani H; Sugitani I; Takeuchi K; Ohashi R
Endocr J; 2022 Mar; 69(3):273-281. PubMed ID: 34732604
[TBL] [Abstract][Full Text] [Related]
8. Expression of protein disulfide isomerase A3 and its clinicopathological association in gastric cancer.
Shimoda T; Wada R; Kure S; Ishino K; Kudo M; Ohashi R; Fujita I; Uchida E; Yoshida H; Naito Z
Oncol Rep; 2019 Apr; 41(4):2265-2272. PubMed ID: 30720117
[TBL] [Abstract][Full Text] [Related]
9. Combination of CALR and PDIA3 is a potential prognostic biomarker for non-small cell lung cancer.
Wang K; Li H; Chen R; Zhang Y; Sun XX; Huang W; Bian H; Chen ZN
Oncotarget; 2017 Nov; 8(57):96945-96957. PubMed ID: 29228584
[TBL] [Abstract][Full Text] [Related]
10. Clinical Significance of Serum Haptoglobin and Protein Disulfide-Isomerase A3 in the Screening, Diagnosis, and Staging of Colorectal Cancer.
Niu Y; Xue J; Wu X; Qu M; Wang L; Liang W; Li T
Front Pharmacol; 2022; 13():935500. PubMed ID: 35860021
[No Abstract] [Full Text] [Related]
11. Expression of protein disulfide isomerase A3 precursor in colorectal cancer.
Yang Z; Liu J; Shi Q; Chao Y; Di Y; Sun J; Zhang J; Huang L; Guo H; He C
Onco Targets Ther; 2018; 11():4159-4166. PubMed ID: 30050307
[TBL] [Abstract][Full Text] [Related]
12. Decreased PTGDS Expression Predicting Poor Survival of Endometrial Cancer by Integrating Weighted Gene Co-Expression Network Analysis and Immunohistochemical Validation.
Zou R; Zheng M; Tan M; Xu H; Luan N; Zhu L
Cancer Manag Res; 2020; 12():5057-5075. PubMed ID: 32617019
[TBL] [Abstract][Full Text] [Related]
13. Identification and validation of TNFRSF4 as a high-profile biomarker for prognosis and immunomodulation in endometrial carcinoma.
Ma H; Feng PH; Yu SN; Lu ZH; Yu Q; Chen J
BMC Cancer; 2022 May; 22(1):543. PubMed ID: 35562682
[TBL] [Abstract][Full Text] [Related]
14. Elevated expression of LPCAT1 predicts a poor prognosis and is correlated with the tumour microenvironment in endometrial cancer.
Zhao T; Zhang Y; Ma X; Wei L; Hou Y; Sun R; Jiang J
Cancer Cell Int; 2021 May; 21(1):269. PubMed ID: 34016103
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value and Immune-Infiltration Pattern of
Yang Z; Shen X; Luo S; Li Y
Dis Markers; 2022; 2022():9621701. PubMed ID: 35126794
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of protein disulfide-isomerase A3 isoforms, PDIA3 and PDIA3N, in human prostate cancer cell lines representing different stages of prostate cancer.
Diaz Cruz MA; Karlsson S; Szekeres F; Faresjö M; Lund D; Larsson D
Mol Biol Rep; 2021 Mar; 48(3):2429-2436. PubMed ID: 33761087
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological features and CCT2 and PDIA2 expression in gallbladder squamous/adenosquamous carcinoma and gallbladder adenocarcinoma.
Zou Q; Yang ZL; Yuan Y; Li JH; Liang LF; Zeng GX; Chen SL
World J Surg Oncol; 2013 Jun; 11():143. PubMed ID: 23782473
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of PDIA3 and its association with cancer cell proliferation and poor prognosis in hepatocellular carcinoma.
Takata H; Kudo M; Yamamoto T; Ueda J; Ishino K; Peng WX; Wada R; Taniai N; Yoshida H; Uchida E; Naito Z
Oncol Lett; 2016 Dec; 12(6):4896-4904. PubMed ID: 28101228
[TBL] [Abstract][Full Text] [Related]
19. Protein Disulfide Isomerase A3 (PDIA3): A Pharmacological Target in Glioblastoma?
Paglia G; Minacori M; Meschiari G; Fiorini S; Chichiarelli S; Eufemi M; Altieri F
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686085
[TBL] [Abstract][Full Text] [Related]
20. PDIA3 correlates with clinical malignant features and immune signature in human gliomas.
Zhang H; Zhou Y; Cheng Q; Dai Z; Wang Z; Liu F; Fan F; Cui B; Cao H
Aging (Albany NY); 2020 Aug; 12(15):15392-15413. PubMed ID: 32687065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
